School of Life Science and Food Engineering, Huaiyin Institute of Technology, Huaian 223003, China.
Department of Medicine, Federal University of Juiz de Fora, Juiz de Fora-MG 36036-900, Brazil.
Mar Drugs. 2021 Mar 30;19(4):196. doi: 10.3390/md19040196.
Naturally occurring biological entities with extractable and tunable structural and functional characteristics, along with therapeutic attributes, are of supreme interest for strengthening the twenty-first-century biomedical settings. Irrespective of ongoing technological and clinical advancement, traditional medicinal practices to address and manage inflammatory bowel disease (IBD) are inefficient and the effect of the administered therapeutic cues is limited. The reasonable immune response or invasion should also be circumvented for successful clinical translation of engineered cues as highly efficient and robust bioactive entities. In this context, research is underway worldwide, and researchers have redirected or regained their interests in valorizing the naturally occurring biological entities/resources, for example, algal biome so-called "treasure of untouched or underexploited sources". Algal biome from the marine environment is an immense source of excellence that has also been demonstrated as a source of bioactive compounds with unique chemical, structural, and functional features. Moreover, the molecular modeling and synthesis of new drugs based on marine-derived therapeutic and biological cues can show greater efficacy and specificity for the therapeutics. Herein, an effort has been made to cover the existing literature gap on the exploitation of naturally occurring biological entities/resources to address and efficiently manage IBD. Following a brief background study, a focus was given to design characteristics, performance evaluation of engineered cues, and point-of-care IBD therapeutics of diverse bioactive compounds from the algal biome. Noteworthy potentialities of marine-derived biologically active compounds have also been spotlighted to underlying the impact role of bio-active elements with the related pathways. The current review is also focused on the applied standpoint and clinical translation of marine-derived bioactive compounds. Furthermore, a detailed overview of clinical applications and future perspectives are also given in this review.
具有可提取和可调结构和功能特性以及治疗属性的天然存在的生物实体,对于加强 21 世纪的生物医学环境非常重要。尽管技术和临床进展不断,但传统的医学实践在解决和管理炎症性肠病 (IBD) 方面效率低下,并且所给予的治疗线索的效果有限。为了成功地将工程线索转化为高效、稳健的生物活性实体,还应避免合理的免疫反应或入侵。在这种情况下,全世界都在进行研究,研究人员已经重新关注或重新获得了利用天然存在的生物实体/资源的兴趣,例如藻类生物群,所谓的“未开发或利用不足的资源宝库”。海洋环境中的藻类生物群是卓越的巨大来源,也已被证明是具有独特化学、结构和功能特征的生物活性化合物的来源。此外,基于海洋来源的治疗和生物线索的新型药物的分子建模和合成可以显示出更大的疗效和特异性。本文努力涵盖了利用天然存在的生物实体/资源来解决和有效管理 IBD 的现有文献差距。在简要的背景研究之后,重点介绍了不同藻类生物群中生物活性化合物的设计特点、工程线索的性能评估以及即时 IBD 治疗。还强调了海洋衍生生物活性化合物的显著潜力,以强调生物活性元素及其相关途径的影响作用。本综述还侧重于海洋衍生生物活性化合物的应用观点和临床转化。此外,本文还详细概述了临床应用和未来展望。